euro-infectious-diseases-2016_keynote

2 / 6

Volume 4, Issue 5(Suppl) J Infect Dis Ther
ISSN: 2332-0877 JIDT, an open access journal Euro Infectious Diseases 2016
September 05-06, 2016
Page 8
Notes:
conferenceseries.com
Infectious Diseases
September 05-06, 2016 Frankfurt, Germany
3rd Euro-Global Conference on
New technologies for innovative needle-free vaccines
Traditional vaccines consist of attenuated or inactivated pathogens, whereas subunit vaccines are based on purified antigens.
Although it would be preferable to exploit noninvasive administration strategies, most vaccines still made use of needles.
In this regard, mucosal vaccines and nanoparticle (NP)-based formulations delivered by transfollicular (TF) route are gaining
interest. However, poor immunogenicity and transport across barriers limit these approaches. Adjuvantation might overcome
these constraints, but only few adjuvants are available for human use and none is active by mucosal route. Our adjuvant
development program led to the discovery of well-defined synthetic immune modulators, which are active when administered
bymucosal route and improve the efficacy of NP-based formulations. Among them, cyclic-di-nucleotides (CDNs) exhibit strong
immune modulatory effects on antigen presenting cells by activation of the type-I IFN and TNF pathways. Co-administration
of CDNs with purified antigens induces strong humoral and cellular responses, which were characterized by a balanced Th1/
Th2 profile and induction of cytotoxic cells. Influenza vaccines adjuvanted with CDNs confer protection against virus challenge
in different preclinical models, including aged mice. Co-administration or formulation with antigen loaded NPs also allowed
triggering antigen specific humoral and cytotoxic responses after TF vaccination, even with a completely intact skin barrier.
This new generation of synthetic adjuvants with well defined molecular targets represents a powerful tool for the rational
design of novel vaccines and immune therapies.
Biography
Carlos Alberto Guzman has graduated in Medicine and become board certified in Medical Bacteriology in Argentina. Later, he was graduated as a Doctor of
Medicine and Surgery and obtained his Doctorate in Microbiological Sciences, University Genoa, Italy. In 1994, he became Head of the Vaccine Group at German
Research Centre for Biotechnology, Germany. In 2005, he was appointed as the Head of the Department of Vaccinology and Applied Microbiology (HZI), becoming
later APL-Professor at the Medical School and Member of the Centre for Individualized Infection Medicine, Hannover. His work was instrumental for developing new
adjuvants and antigen delivery systems, leading to more than 200 publications.
Carlos Alberto Guzman
Helmholtz Centre for Infection Research, Germany
Carlos Alberto Guzman, J Infect Dis Ther 2016, 4:5(Suppl)